Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial

Author:

Wolfrum Sebastian12,Roedl Kevin3ORCID,Hanebutte Alexia12,Pfeifer Rüdiger4,Kurowski Volkhard35,Riessen Reimer6,Daubmann Anne7,Braune Stephan3,Söffker Gerold3ORCID,Bibiza-Freiwald Eric7,Wegscheider Karl78ORCID,Schunkert Heribert29ORCID,Thiele Holger10ORCID,Kluge Stefan3,

Affiliation:

1. Emergency Department (S.W., A.H.), University of Luebeck, Germany.

2. Medical Clinic II, Department of Cardiology, Angiology and Intensive Care Medicine (S.W., A.H., V.K., H.S.), University of Luebeck, Germany.

3. Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany.

4. Department of Internal Medicine 1, University Hospital of Jena, Germany (R.P.).

5. Department of Cardiology and Intensive Care Medicine, DRK Hospital, Ratzeburg, Germany (V.K.).

6. Department of Medicine, Medical Intensive Care Unit, University of Tübingen, Germany (R.R.).

7. Institute of Medical Biometry and Epidemiology (A.D., E.B.-F.‚ K.W.), University Medical Centre Hamburg-Eppendorf, Germany.

8. German Centre for Cardiovascular Research (DZHK e.V.)‚ Partner Site Hamburg/Kiel/Lübeck‚ Hamburg‚ Germany (K.W.).

9. German Heart Center Munich, Department of Cardiology‚ Technical University of Munich‚ German Center for Cardiovascular Research (DZHK) - Munich Heart Alliance (H.S.).

10. Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Germany (H.T.).

Abstract

Background: This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac arrest (IHCA) on mortality and functional outcome as compared with normothermia. Methods: An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing hypothermic temperature control (32-34°C) for 24 h with normothermia after IHCA in 11 hospitals in Germany. The primary endpoint was all-cause mortality after 180 days. Secondary end points included in-hospital mortality and favorable functional outcome using the Cerebral Performance Category scale after 180 days. A Cerebral Performance Category score of 1 or 2 was defined as a favorable functional outcome. Results: A total of 1055 patients were screened for eligibility and 249 patients were randomized: 126 were assigned to hypothermic temperature control and 123 to normothermia. The mean age of the cohort was 72.6±10.4 years, 64% (152 of 236) were male, 73% (166 of 227) of cardiac arrests were witnessed, 25% (57 of 231) had an initial shockable rhythm, and time to return of spontaneous circulation was 16.4±10.5 minutes. Target temperature was reached within 4.2±2.8 hours after randomization in the hypothermic group and temperature was controlled for 48 hours at 37.0°±0.9°C in the normothermia group. Mortality by day 180 was 72.5% (87 of 120) in hypothermic temperature control arm, compared with 71.2% (84 of 118) in the normothermia group (relative risk, 1.03 [95% CI, 0.79–1.40]; P =0.822). In-hospital mortality was 62.5% (75 of 120) in the hypothermic temperature control as compared with 57.6% (68 of 118) in the normothermia group (relative risk, 1.11 [95% CI, 0.86–1.46, P =0.443). Favorable functional outcome (Cerebral Performance Category 1 or 2) by day 180 was 22.5% (27 of 120) in the hypothermic temperature control, compared with 23.7% (28 of 118) in the normothermia group (relative risk, 1.04 [95% CI, 0.78–1.44]; P =0.822). The study was prematurely terminated because of futility. Conclusions: Hypothermic temperature control as compared with normothermia did not improve survival nor functional outcome at day 180 in patients presenting with coma after IHCA. The HACA in-hospital trial (Hypothermia After Cardiac Arrest in-hospital) was underpowered and may have failed to detect clinically important differences between hypothermic temperature control and normothermia. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT00457431.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3